Eligibility for anti-amyloid treatment in a multiethnic community-based study
{{output}}
Introduction: The approval of anti-amyloid monoclonal antibodies (mAbs), including lecanemab and donanemab, represents a significant advance in disease-modifying therapies (DMTs) for early Alzheimer's disease (AD). While appropr... ...
